Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_provenance.
- NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_assertion description "[First, immune-based therapies are being developed (eg, elotuzumab monoclonal antibody [MoAb]; CD138DM immunotoxin; MM cell-dendritic cell vaccines; CD138, CS-1, and XBP-1 peptide vaccines; anti-17 MoAb; and other treatments to overcome causes of immune dysfunction).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_provenance.
- NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_assertion evidence source_evidence_literature NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_provenance.
- NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_assertion SIO_000772 22215754 NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_provenance.
- NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_assertion wasDerivedFrom befree-20140225 NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_provenance.
- NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_assertion wasGeneratedBy ECO_0000203 NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_provenance.
- befree-20140225 importedOn "2014-02-25" NP506791.RAFYihQGw511rOEnLY2OHL4rKodMyy7WLx7GwTByFny0o130_provenance.